Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

InMed Pharmaceuticals Inc INM

Healthcare Cannabis
InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.


NDAQ:INM - Post by User

InMed Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(0)
•••
Comment by Balzdepeon Nov 01, 2017 7:56pm
101 Views
Post# 26891350

RE:RE:RE:TO ALL SHORTERS

RE:RE:RE:TO ALL SHORTERS
Date Short Sale Trades % Total Trades Short Traded Volume % Total Traded Volume Short Traded Value % Total Traded Value
Jan 2 2017 253 17.246 1,376,552 14.882 $282,740 13.844
Jan 16 2017 247 15.163 963,547 10.420 $252,259 10.390
Feb 1 2017 901 19.960 3,650,088 20.389 $1,572,087 20.535
Feb 16 2017 596 20.817 2,067,233 20.131 $815,593 20.241
Mar 1 2017 673 29.021 2,837,476 29.373 $1,132,936 29.533
Mar 16 2017 373 17.686 1,102,190 13.959 $396,922 13.955
Apr 3 2017 371 15.834 1,109,564 12.859 $454,775 12.974
Apr 17 2017 2,297 24.954 7,022,463 26.104 $5,556,947 27.097
May 1 2017 1,595 30.214 4,305,704 30.937 $3,279,719 30.784
May 16 2017 2,311 54.096 3,803,677 40.389 $2,124,264 40.217
Jun 1 2017 1,458 43.123 5,680,200 43.755 $2,655,577 42.534
Jun 16 2017 506 22.711 2,023,307 23.338 $742,900 23.154
Jul 3 2017 134 12.909 249,553 6.702 $88,263 6.725
Jul 17 2017 96 14.056 231,678 8.953 $76,440 9.057
Aug 1 2017 96 9.222 214,561 5.922 $70,242 5.905
Aug 16 2017 260 25.591 856,585 17.984 $234,501 17.414
Sep 1 2017 180 20.225 308,069 9.497 $89,883 9.517
Sep 18 2017 464 19.512 1,613,200 16.209 $650,061 16.705
Oct 2 2017 466 15.717 1,713,234 14.669 $808,275 14.695
Oct 16 2017 358 22.875 1,232,343 24.640 $603,741 24.897
Nov 1 2017 556 19.971 1,434,606 15.693 $607,276 15.756
Not much volume in shorting from what I see lately. Is this really a problem?
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities